Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Nasopharyngeal Carcinoma 7Esophageal Squamous Cell Carcinoma 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms 2Advanced Breast Cancer 2Urinary Bladder Neoplasms 1Turcot syndrome 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Recurrence 1Papillomavirus Infections 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

toripalimab 1disitamab vedotin 1Probiotics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Cancer (MIBC) × toripalimab × 90 days × Clear all
NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
146 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡